CSL Seqirus expands U.S. availability of influenza vaccine
CSL•CSL Seqirus said it expanded U.S. availability of its influenza vaccine following successful completion of the 2026/27 manufacturing campaign.
1. Vaccine availability
CSL Seqirus said it expanded U.S. availability of its influenza vaccine following successful completion of the 2026/27 manufacturing campaign.
